PhoreMost Ltd

PhoreMost Ltd is a biotechnology and biopharmaceutical company based in Cambridge, UK.

The company focuses on developing innovative cancer therapies by targeting "undruggable" disease sites. With roots as a Cambridge University spin-out, PhoreMost has established itself as a leader in drug discovery, emphasizing the identification of novel disease targets rather than repurposing existing ones. Its pipeline includes next-generation drug targets, particularly in oncology and inflammation. The company's proprietary phenotypic screening platform, SITESEEKER®, plays a crucial role in its research. This platform utilizes live-cell dynamics to discover hidden druggable target sites across the human genome, facilitating the rapid development of new small-molecule therapeutics. PhoreMost is advancing several key products, including PMC-001, aimed at treating brain cancers, and SOL686, a novel inhibitor for glioma. The company targets patients with high unmet clinical needs, including those with brain cancers and neurodegenerative disorders, while also collaborating with the biopharmaceutical and oncology research community.